328 Chapter 12 ACKNOWLEDGMENTS We thank Vala Sciences directors Jeffrey H. Price and Patrick M. McDonough for the Cyteseer Software package to analyze the Ca2+ transients in the hCSs. We thank Prof. Joseph C. Wu from Stanford University for providing the control line 273iCTR. We thank Prof. Mark Mercola from Stanford University for providing the isogenic control line C31iCTR and the PLN-R14del patient line D4iR14del. We thank Stef Houweling for the Ca2+ handling screenings, and Christian Snijders Blok for the flow cytometry analysis. We thank the PLN foundation for providing the proband control line 1CiCTR and the PLN-R14del patient lines; 6BiR14del and 10BiR14del FUNDING R.G.C.M is supported by the PLN Foundation and the grant HARVEY (18747 NWO-OTP). P.A.D. is supported by CUREPLaN Leducq. J.P.G.S. is supported by H2020-EVICARE (#725229) of the European Research Council (ERC). P.A.D and J.P.G.S are supported by ZonMW Psider-Heart and HARVEY (18747 NWO-OTP). J.W.B. is supported by a Dekker grant from the Dutch Heart Foundation (03-003-2021-T025), Netherlands Heart Institute Fellowship, and CVON-Dosis young talent grant; Netherlands Heart Foundation (CVON-Dosis 2014–40). CONFLICTS OF INTEREST The authors declare that there is no conflict of interest regarding the publication of this paper.
RkJQdWJsaXNoZXIy MTk4NDMw